Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on α1-adrenoceptor antagonists

BJU International, Supplement

Volumn 95, Issue 4, 2005, Pages 29-36

  Milani, Shirin ^a   Djavan, Bob ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

1 adrenoceptor antagonists; Alfuzosin; BPH; Doxazosin; Efficacy; LUTS; Tamsulosin; Terazosin; Tolerability

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; TAMSULOSIN; TERAZOSIN;

BLOOD PRESSURE REGULATION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; EJACULATION DISORDER; HEADACHE; HEART PALPITATION; HUMAN; MALE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SEXUAL FUNCTION; SYNCOPE; TACHYCARDIA; URINARY TRACT DISEASE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; EJACULATION; HUMANS; MALE; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME;

EID: 18944402458     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05485.x     Document Type: Review

References (63)

1. Crawford ED. Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profile. BJU Int 2005; 95 (Suppl. 4): 1-5
2. Barendrecht MM, Koopmans RP, De La Rosette JJ, Michel MC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. BJU Int 2005; 95 (Suppl. 4): 19-28
3. Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 2005; 95 (Suppl. 4): 12-18
4. Trachtenberg J. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progression. BJU Int 2005; 95 (Suppl. 4): 6-11
5. AUA practice guidelines committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530-47
6. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13
7. Djavan B, Chapple CR, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 2004; 64: 1081-8
8. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet 1991; 337: 1457-61
9. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFTECH Study Group. Scand J Urol Nephrol Suppl 1994; 157: 169-76
10. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997; 31: 190-8
11. van Kerrebroeck P, Jardin A, Laval KU, van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37: 306-13
12. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomised, placebo-controlled trial. Urology 2001; 58: 953-9
13. Roehrborn CG, van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-61
14. Lepor H, Auerbach S, Puras-Baez A et al. A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467-74
15. Di Silverio F. Use of terazosin in the medical treatment of benign prostatic hyperplasia: experience in Italy. Br J Urol 1992; 70 (Suppl. 1): 22-6
16. Lloyd SN, Buckley JF, Chilton CP, Ibrahim I, Kaisary V, Kirk D. Terazosin in the treatment of benign prostatic hyperplasia: a multicentre, placebo-controlled trial. Br J Urol 1992; 70 (Suppl. 1): 17-21
17. Brawer MK, Adams G, Epstein H. Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group. Arch Fam Med 1993; 2: 929-35
18. Roehrborn CG, Oesterling JE, Auerbach S et al. The Hytrin Community Assessment Trial Study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology 1996; 47: 159-68
19. Lepor H, Williford WO, Barry MJ et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Eng J Med 1996; 335: 533-9
20. Elhilali MM, Ramsey EW, Barkin J et al. A multicenter, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology 1996; 47: 335-42
21. Christensen MM, Bendix Holme J, Rasmussen PC et al. Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. Scan J Urol Nephrol 1993; 27: 39-44
22. Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-9
23. Gillenwater JY, Conn RL, Chrysant SG et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-15
24. Mobley DF, Kaplan S, Ice K, Gaffney M, Dias N. Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies. Int J Clin Pract 1997; 51: 282-8
25. Roehrborn CG, Siegel RL. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 1996; 48: 406-15
26. Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol 1993; 24: 319-26
27. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61: 119-26
28. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride and combination therapy on the clinical progression of benign prostatic hyperplasia. N Eng J Med 2003; 349: 2387-98
29. Andersen M, Dahlstrand C, Hoye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 2000; 38: 400-9
30. Kirby RS, Andersen M, Gratzke P, Dahlstrand C, Hoye K. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 2001; 87: 192-200
31. 1C-adrenoceptor antagonist: a randomised, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995; 76: 325-36
32. 1A-adrenoceptor antagonist. A meta-analysis of two randomised, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 155-67
33. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998; 51: 892-900
34. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-6
35. Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701-6
36. Buzelin JM, Fonteyne E, Kontturi M, Witjes WP, Khan A. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. Br J Urol 1997; 80: 597-605
37. CDER New and Generic Drug Approvals: 1998-2004. URL http:// www.fda.gov/cder/approval/index.htm [accessed 24 February 2005]
38. Lowe F, Narayan P, Djavan B. Prospective, randomised, multicentre trial to evaluate the rapidity of onset and side effect profile of tamsulosin (TAM) vs terazosin (TER) in men with benign prostatic hyperplasia (BPH). Eur Urol Suppl 2002; 1: 108 (Abstract 421)
39. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 481-8
40. de Mey C, Terpstra I. Orthostatic effects of alfuzosin twice daily vs. tamsulosin once daily in the morning. J Urol 2000; 163: 220 (Abstract 978)
41. Djavan B. Fast control of the patient's quality of life. Urology 2003; 62 (Suppl 1): 6-14
42. 1-AR antagonists in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/ BPH). Eur Urol Suppl 2005; 4: in press
43. de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being. Eur Urol 1998; 34 (Suppl. 2): 18-28
44. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731-40
45. Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C. Safety profile of 3 months' therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996; 29: 29-35
46. Lukacs B, Grange JC, Comet D, McCarthy C. History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. Eur Urol 2000; 37: 183-90
47. Roehrborn C, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once daily: a pooled analysis of three double-blind placebo-controlled studies. Eur Urol Suppl 2002; 1: 106 (Abstract 416)
48. van Kerrebroeck P, Jardin A, van Cangh P, Laval KU. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002; 41: 54-61
49. Chapple CR, Baert L, Thind P. Höfner K, Khoe GS, Spångberg A. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997;32:462-70
50. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schäfers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998; 160: 784-91
51. 1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects. J Int Med Res 2001; 29: 236-51
52. 1-Adrenoceptor antagonists for treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): state of the art. Eur Urol Suppl 2004; 3: 23-30
53. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther 1997; 19: 730-42
54. Kloner RA, Jackson G, Emmick JT et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004; 172: 1935-40
55. Kloner RA. Novel phoshodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. Clin Cardiol 2004; 27 (Suppl. 1): 120-5
56. Auerbach S, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology 2004; 64: 998-1004
57. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 335-41
58. Giuliano F, Bernabe J, Droupy S, Alexandre L, Allard J. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increased in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 605-8
59. 1-adrenoceptor antagonists. BJU Int 2004; 94: 443-5
60. Speakman MJ, Snijder RJ, Anthonijs G, Doyle CA. Patients on tamsulosin experiencing abnormal ejaculation choose to remain longer in clinical trials and have a slightly better improvement in symptom score than other patients. J Urol 2003; 169 (Suppl. 4): 334 (Abstract 1296)
61. Lukacs B, Leplege A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731-40.
62. Vallancien G. Sexual function assessed by the BSFI is improved with alfuzosin 10mg once daily. Eur Urol Suppl 2004; 3: 91 (Abstract 353)
63. Coffey DS. Controversies in the management of lower urinary tract symptoms: an overview. Br J Urol 1998; 81 (Suppl. 1): 1-5